Table 1

Figures at a glance

Figure 1

Table 1

Case	Age	Sex	HBV DNA (IU/mL)	Other infection	Bilirubin (umol/L)		HIV RNA (copies/mL)			CD4 counts/μL
Case	Age	Sex	HBV DNA (IU/mL)	Other infection	Pre	Week 4	Pre	Week 4 (Log reduction)	*Week 8-12**	Pre	Week 4	Week 28
1	52	F	Negative	Non-TB, mycobacteria	61.5	6.9	59,200	2,160 (-1.44)	<20*	3	29	139
2	30	M	129,000	T Marneffei	40	6.3	80,200	33,100 (-0.38)	<20*	39	86	178
3	47	M	45,500	T Marneffei	134	48.7	39,000	234 (-2.22)	<20*	37	170	218
4	38	M	738,000	T Marneffei	23.6	4.8	999,000	56,000 (-1.25)	<20	4	19	164
5	71	M	56,000	TB plus T Marneffei	52.6	18.9	139,000	46,200 (-0.48)	<20	82	92	217
6	29	M	Negative	TB plus T Marneffei	75.4	5.78	2,090,000	376,000 (-0.74)	<20	65	176	284
7	39	M	Negative	TB plus T Marneffei	48.6	5.99	500,000	88,800 (-0.75)	<20*	4	134	220

Table 1: HIV patients with severe liver impairment treated with ABT/3TC/TDF regimen

*Evaluation at week 8 after initiation of ABT/3TC/TDF regimen

FIGURE 1

Figure 1: Dynamic changes of HIV RNA (A), CD4 counts (B) and Bilirubin (C) at baseline and different time points

All showed significant decrease in HIV RNA at 4 weeks post treatment and were less than 20 copies/mL by week 8 to 12 and remained undetectable at subsequent visits. All had CD4 counts above 130 cells/μl between week 12 and week 16 of therapy. All but one patients had normalization of bilirubin by week 12